Company: G
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001398659-25-000109
Chunk: 154

Company: Genpact LTD
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 154
---
4 and the nine months ended September 30, 2025 was $55,870 and $59,952, respectively. The principal amount outstanding against this facility as of December 31, 2024 and September 30, 2025 was $26,583 and $54,274, respectively. The cost of factoring such accounts receivable during the three and nine months ended September 30, 2024 and 2025 was $589 and $498, respectively, and $2,015 and $1,579, respectively. Gains or losses on the sales are recorded at the time of transfer of the accounts receivable and are included under "interest income (expense), net" in the Company’s consolidated statements of income.

20

GENPACT LIMITED AND ITS SUBSIDIARIESNotes to the Consolidated Financial Statements(Unaudited)(In thousands, except per share data and share count)

4. Accounts receivable, net of allowance for credit losses ( Continued)The Company also has arrangements with financial institutions that manage the accounts payable program for certain of the Company's large clients. The Company sells certain accounts receivable pertaining to such clients to these financial institutions on a non-recourse basis. There is no cap on the value of accounts receivable that can be sold under these arrangements. The Company used these arrangements to sell accounts receivable amounting to $270,211 during the year ended December 31, 2024 and $229,003 during the nine months ended September 30, 2025, which also represents the maximum capacity utilized under these arrangements in each such period. The cost of factoring such accounts receivable during the three and nine months ended September 30, 2024 and 2025 was $1,395 and $1,557, respectively, and $4,436 and $4,137, respectively. These costs are included under "interest income (expense), net" in the Company’s consolidated statements of income.

5. Fair value measurements

 The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these financial assets and liabilities were determined using the following inputs as of December 31, 2024 and September 30, 2025: As of December 31, 2024Fair Value Measurements at Reporting Date UsingQuoted Prices inActive Markets forIdentical AssetsSignificant Other Observable InputsSignificant Other UnobservableInputsTotal